Ocugen (OCGN) Net Cash Flow Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 89.97% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -13.44% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 33.37% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -29.82% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 32.17% |
| 10 | Ocugen | 452.01 Mn | 452.01 Mn | - | 50.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 50.62% |
| Dec 31, 2025 | 16.50% |
| Sep 30, 2025 | 34.08% |
| Jun 30, 2025 | 10.35% |
| Mar 31, 2025 | -37.41% |
| Dec 31, 2024 | 53.23% |
| Sep 30, 2024 | 68.38% |
| Jun 30, 2024 | -29.00% |
| Mar 31, 2024 | -38.05% |
| Dec 31, 2023 | -69.15% |
| Sep 30, 2023 | -83.05% |
| Jun 30, 2023 | -41.80% |
| Mar 31, 2023 | -29.83% |
| Dec 31, 2022 | -45.16% |
| Sep 30, 2022 | -42.90% |
| Jun 30, 2022 | -248.62% |
| Mar 31, 2022 | 205.08% |
| Dec 31, 2021 | -143.76% |
| Sep 30, 2021 | -15.67% |
| Jun 30, 2021 | 132.20% |
| Mar 31, 2021 | 35.05% |
| Dec 31, 2020 | 49.29% |
| Sep 30, 2020 | 159.79% |
| Jun 30, 2020 | 59.08% |
| Mar 31, 2020 | 35.08% |
| Dec 31, 2019 | -8.89% |
| Sep 30, 2019 | -12.82% |
| Jun 30, 2019 | 27.10% |
| Mar 31, 2019 | 45.21% |
| Dec 31, 2018 | 51.01% |
| Sep 30, 2018 | 10.60% |
| Jun 30, 2018 | 5.41% |
| Mar 31, 2018 | 55.04% |
| Dec 31, 2017 | -27.39% |
| Sep 30, 2017 | 27.08% |
| Jun 30, 2017 | -49.12% |
| Mar 31, 2017 | -42.45% |